Low GATA3 Predicts Worse Survival in Penile Cancer - Beyond the Abstract
Penile squamous cell carcinoma (pSCC) remains a rare but clinically challenging malignancy with limited improvement in outcomes over recent decades. While traditional prognostic factors such as tumor stage, grade, and lymph node status are well established, there is a growing need for robust and easily applicable biomarkers that could refine risk stratification and potentially guide therapeutic decision-making.
In this study, Hrudka et al. analyzed a relatively large retrospective cohort of 145 patients with pSCC, focusing on a panel of immunohistochemical markers routinely available in diagnostic practice. Among the evaluated markers (GATA3, IMP3, HIF-1α, CK7, CA-IX, HER2, and TTF-1), only low GATA3 expression demonstrated a statistically significant association with worse overall survival. Notably, this effect was most pronounced in early follow-up (3 years), where GATA3-low tumors showed a markedly increased hazard of death. Furthermore, low GATA3 expression correlated with adverse pathological features, including advanced tumor stage and lymphatic invasion, supporting its role as a marker of aggressive tumor biology.
Interestingly, other markers such as IMP3, CK7, and CA-IX—despite being linked to unfavorable tumor characteristics like higher grade or nodal metastases—did not independently predict survival. This highlights an important distinction between markers reflecting tumor biology and those with true prognostic utility. The lack of prognostic impact of HIF-1α, particularly in the context of cytoplasmic-only expression, further underscores the complexity of biomarker interpretation and the importance of methodological nuances.
From a biological perspective, GATA3 is a transcription factor involved in epithelial differentiation, and its loss has been associated with dedifferentiation and more aggressive phenotypes in several tumor types. The findings in pSCC are consistent with observations in vulvar squamous cell carcinoma, suggesting that GATA3 loss may represent a common pathway in HPV-independent carcinogenesis.
Clinically, the appeal of GATA3 lies in its immediate applicability. As an immunohistochemical marker already widely used in routine pathology, its incorporation into diagnostic workflows would be straightforward. However, it remains unclear whether GATA3 provides independent prognostic information beyond established parameters in fully adjusted models, and prospective validation in independent cohorts is warranted.
Written by: Jan Hrudka, Department of Pathology, Charles University in Prague, 3rd Faculty of Medicine, Prague, Czech Republic
Read the Abstract